🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being described as a "major milestone" in the fight against superbug strains of the infection, according to scientists.

A Worldwide Challenge

The sexually transmitted infection are increasing worldwide, with estimates suggesting over 82 million new cases each year. Particularly high rates are seen in Africa and countries within the World Health Organization's Western Pacific region, which encompasses Mongolia and China to New Zealand. In England, cases have hit a record high, while infection numbers across Europe in 2023 were three times higher compared to figures for 2014.

“The authorization of novel therapies for gonorrhoea is an significant and necessary advancement in the reality of increasing worldwide cases, the spread of superbugs and the highly restricted treatment choices at this time.”

Public health authorities are increasingly worried about the increase in drug-resistant strains. The global health body has classified it as a "critical concern". A tracking program found that resistance to primary antibiotics like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

Two New Drugs Secure Approval

Zoliflodacin, marketed under the name a brand name, was approved by the American regulatory agency in mid-December for combating gonorrhoea. This STI can lead to significant complications, including the inability to conceive. Researchers anticipate that specific application of this new drug will help hinder the emergence of superbugs.

Gepotidacin, developed by the drugmaker GSK, was also approved in concurrent days. This drug, which is additionally indicated for urinary tract infections, was shown in trials to be effective against antibiotic-resistant forms of the gonorrhoea bacteria.

A Novel Development Model

Zoliflodacin was the result of a new, not-for-profit approach for antibiotic development. The charitable organization Global Antibiotic Research & Development Partnership worked alongside the drug firm its industry partner to develop it.

“This authorization signifies a huge turning point in the management of superbug gonorrhoea, which up to this point has been outpacing our drug pipeline.”

Testing Results and Worldwide Availability

Based on data detailed in a prominent scientific publication, the new drug eradicated more than 90% of uncomplicated infections. This places it at an equal footing with the typical regimen, which involves a dual-drug approach. The trial included nearly 1,000 participants from various regions including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its development partnership, GARDP has the ability to register and commercialise the drug in many developing nations.

Doctors directly involved have expressed optimism. The availability of a single-dose, oral treatment such as this is hailed as a "critical tool" for public health efforts. This is deemed vital to alleviate the strain of the illness for individuals and to halt the transmission of extremely resistant gonorrhoea around the world.